These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 38173833)

  • 21. Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma.
    Fenton SE; VanderWeele DJ
    Front Oncol; 2022; 12():1069356. PubMed ID: 36686762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-Drug Conjugates: Ushering in a New Era of Cancer Therapy.
    Hurwitz J; Haggstrom LR; Lim E
    Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential of antibody-drug conjugates (ADCs) for cancer therapy.
    Marei HE; Cenciarelli C; Hasan A
    Cancer Cell Int; 2022 Aug; 22(1):255. PubMed ID: 35964048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers.
    Peng H
    Antib Ther; 2021 Oct; 4(4):222-227. PubMed ID: 34805745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.
    Wang AJ; Gao Y; Shi YY; Dai MY; Cai HB
    Front Pharmacol; 2022; 13():1093666. PubMed ID: 36618922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.
    Schwach J; Abdellatif M; Stengl A
    Front Biosci (Landmark Ed); 2022 Aug; 27(8):240. PubMed ID: 36042167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging treatments in advanced urothelial cancer.
    Alhalabi O; Campbell M; Shah A; Siefker-Radtke A; Gao J
    Curr Opin Oncol; 2020 May; 32(3):232-239. PubMed ID: 32209822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads.
    Monteiro MR; Nunes NCC; Junior AADS; Fêde ABS; Bretas GO; Souza CP; Mano M; da Silva JL
    Breast Cancer (Dove Med Press); 2024; 16():51-70. PubMed ID: 38434801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-Drug Conjugates: The Last Decade.
    Joubert N; Beck A; Dumontet C; Denevault-Sabourin C
    Pharmaceuticals (Basel); 2020 Sep; 13(9):. PubMed ID: 32937862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current methods for the synthesis of homogeneous antibody-drug conjugates.
    Sochaj AM; Świderska KW; Otlewski J
    Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-Drug Conjugates in Urothelial Carcinomas.
    Sarfaty M; Rosenberg JE
    Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.
    Sheyi R; de la Torre BG; Albericio F
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-Drug Conjugates as an Emerging Therapy in Oncodermatology.
    Esnault C; Schrama D; Houben R; Guyétant S; Desgranges A; Martin C; Berthon P; Viaud-Massuard MC; Touzé A; Kervarrec T; Samimi M
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs.
    Jiang Y; Zhou H; Liu J; Ha W; Xia X; Li J; Chao T; Xiong H
    Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.